GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (NAS:OCUL) » Definitions » Cash Flow from Investing

Ocular Therapeutix (Ocular Therapeutix) Cash Flow from Investing : $-6.09 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Ocular Therapeutix Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Ocular Therapeutix spent $0.46 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Ocular Therapeutix spent $0.46 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Ocular Therapeutix Cash Flow from Investing Historical Data

The historical data trend for Ocular Therapeutix's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Cash Flow from Investing Chart

Ocular Therapeutix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.24 -0.84 -1.19 -3.72 -6.09

Ocular Therapeutix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.15 -3.38 -1.99 -0.26 -0.46

Ocular Therapeutix Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Ocular Therapeutix's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Ocular Therapeutix's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocular Therapeutix  (NAS:OCUL) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Ocular Therapeutix's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-0.46 Mil. It means Ocular Therapeutix spent $0.46 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Ocular Therapeutix's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Ocular Therapeutix gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Ocular Therapeutix's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Ocular Therapeutix spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Ocular Therapeutix's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Ocular Therapeutix gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Ocular Therapeutix's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Ocular Therapeutix spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Ocular Therapeutix's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Ocular Therapeutix gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Ocular Therapeutix's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Ocular Therapeutix paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Ocular Therapeutix's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Ocular Therapeutix paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Ocular Therapeutix's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Ocular Therapeutix paid $0.00 Mil for other investing activities.


Ocular Therapeutix Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix (Ocular Therapeutix) Business Description

Traded in Other Exchanges
Address
24 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Executives
Summer Road Llc 10 percent owner 207 6TH STREET, WEST PALM BEACH FL 33401
Antony C. Mattessich director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Rabia Gurses Ozden officer: Chief Medical Officer C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
Philip C. Strassburger officer: General Counsel 24 CROSBY DRIVE, BEDFORD MA 01730
Donald Notman officer: Chief Financial Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Christopher G White officer: Chief Business Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Jeffrey S. Heier director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patricia Kitchen officer: Chief Operations Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Leslie J. Williams director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Seung Suh Hong director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Amarpreet Sawhney director, 10 percent owner, officer: President and CEO C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730

Ocular Therapeutix (Ocular Therapeutix) Headlines